Everything published about Tesamorelin: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 10 mg | from 2 200 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
Tesamorelin is a synthetic growth-hormone-releasing hormone analogue. It stimulates the pituitary GH pathway and is best known for research and clinical use involving visceral abdominal fat.
Licensed pharmaceutical formulations are indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. This is a specific clinical population, rather than a general weight-loss indication.
A GHRH analogue with clinical evidence for visceral-fat reduction in HIV-associated lipodystrophy and a clear focus on body composition.
Controlled trials in HIV-associated lipodystrophy demonstrated reductions in visceral abdominal fat. This is a body-composition effect rather than simply a change on the scale; abdominal fat can return after treatment stops.
Original pivotal trials used 2 mg subcutaneously daily for 26 weeks. Different licensed formulations have daily doses of 2 mg, 1.4 mg or 1.28 mg. These are formulation-specific regimens and are not interchangeable milligram for milligram.
Possible effects include joint discomfort, fluid retention, increased IGF-1 and changes in glucose regulation. Licensed contraindications include active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis.
Both engage the GHRH pathway, but tesamorelin has formulation-specific evidence in a defined clinical indication. CJC-1295 DAC is a different, albumin-binding investigational analogue with much longer exposure.
from 2 200 000 ₫ for 10 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.